Europe Genetic Testing Market Trends

Statistics for the 2023 & 2024 Europe Genetic Testing market trends, created by Mordor Intelligence™ Industry Reports. Europe Genetic Testing trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Single User License
Team License
Corporate License
Book before:

Single User License

OFF

Team License

OFF

Corporate License

OFF
Book before:

Market Trends of Europe Genetic Testing Industry

This section covers the major market trends shaping the Europe Genetic Testing Market according to our research experts:

The Diagnostic Testing Segment is Expected to Hold a Significant Share Over the Forecast Period

The diagnostics testing segment is expected to hold a significant share of the European genetic testing market owing to the factors such as the increasing emphasis on early disease detection and prevention and the rise in product launches in the European market for diagnostic genetic testing. The rise in the number of chronic diseases is also a major factor leading to market growth since early detection is likely to reduce the complications associated with the disease. For instance, according to the European Cancer Information System, the number of new cancer cases in Europe in 2035 is estimated to rise to 3.13 million. As per the same source, the new cancer cases are estimated to rise to 3.24 million by 2040. The rising incidence of cancer cases is anticipated to lead to increased diagnostic testing for cancers in Europe, thereby expected to drive this segment's growth.

Furthermore, the rising product launches for diagnostic testing are likely to lead to increased adoption of these products, thereby expected to drive the growth of this segment. For instance, in February 2021, in Europe, Becton, Dickinson, and Company introduced a new COVID-19 blood test that can assist hospitals in identifying arriving patients who are more likely to require intensive care with a ventilator and are at a higher risk of dying from the disease.

Similarly, in April 2022, Illumina Inc., a company in DNA sequencing and array-based technologies, entered into an agreement with Germany's Hannover Medical School (Medizinische Hochschule Hannover (MHH)) to implement the use of whole-genome sequencing (WGS) in critically ill children suspected of having a genetic or rare disease. The project, led by the Department of Human Genetics at MHH, is likely to evaluate the use of WGS in neonatal and pediatric intensive care unit settings to show the positive impact of earlier diagnosis and treatment for hospitalized children. Hence, the rise in product launches associated with diagnostic testing is likely to boost segment growth over the forecast period.

Hence, due to the increasing focus on early disease detection and prevention, the rise in diagnostic testing product launches, and the increase in chronic diseases that require early diagnosis, the diagnostic testing segment is anticipated to witness growth in the Europe genetic testing market over the forecast period.

Europe Genetic Testing Market: Estimated Incidence of Cancer Cases (in Thousand), by Country, Europe, 2040

United Kingdom is Likely to Witness a Significant Growth in the Market Over the Forecast Period

The United Kingdom is anticipated to witness growth in the Europe genetic testing market owing to the factors such as increasing emphasis on early disease detection and prevention, increasing demand for personalized medicine, and increasing application of genetic testing in oncology. For instance, according to the study published by the University of Manchester in November 2021, whole genome sequencing (WGS) demonstrated to find new diagnoses for persons with the greatest spectrum of rare diseases explored to date, which might have enormous implications for the National Health Service.

Furthermore, the rising benefits of genetic testing for the discovery of rare diseases are likely to lead to the rise in the adoption of genetic testing in this region, thereby expected to drive the growth of this market in the United Kingdom. For instance, in March 2022, the first UK pilot study of newborn screening for spinal muscular atrophy (SMA) was launched in Oxford. Screening is likely to be done through the routine United Kingdom's newborn blood spot screening pathway, using spare capacity from a newborn Guthrie card (dried blood spot sample).

The presence of prominent market players operational in the United Kingdom genetic testing and favorable regulatory scenarios prove advantageous for the market expansion. For instance, in September 2022, the Medicines and Healthcare products Regulatory Agency-registered Orthotype tests from ExplantLab were launched at the Artificial Intelligence in Orthopaedics conference at the Royal College of Surgeons. These new genetic tests are poised to help the United Kingdom to meet its goal of becoming a 'science superpower' by 2030. Orthotype tests identify genetic markers in saliva or blood samples for specific variations of human leukocyte antigen (HLA) genes, which regulate immune responses. Hence, such product launches and collaborations are likely to raise product availability, thereby boosting market growth over the forecast period.

Furthermore, the rise in the number of chronic diseases is also a major factor leading to market growth since early detection is likely to reduce the complications associated with the disease. For instance, according to Macmillan Cancer Support 2022, the number of new cancer cases in the United Kingdom in 2025 is estimated to be 3.5 million. As per the same source, the new cancer cases are estimated to rise to 5.3 million by 2040. The rising incidence of cancer cases is anticipated to lead to increased genetic testing for cancers in the United Kingdom, thereby expected to drive market growth.

Therefore, rising initiatives on genetic testing, the increase in chronic diseases that require early diagnosis, and the rising benefits of genetic testing in rare diseases are likely to lead to increased adoption of genetic testing in the United Kingdom.

Europe Genetic Testing Market: Estimated Number of Cancer Cases (in Million), United Kingdom, 2025-2040

Europe Genetic Testing Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)